Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.
Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.
Jaypirca (pirtobrutinib) is a highly selective kinase inhibitor that utilizes a novel binding mechanism.
Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.
Here are latest arrivals approved by the Food and Drug Administration.
KTE-X19 led to durable remission in a majority of study participants.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.